The role of Uro-Vaxom in reducing infectious adverse effects and improving outcomes in bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer.

ABSTRACT:

Purpose

Intravesical bacillus Calmette-Guerin (BCG) instillation is a cornerstone treatment for non-muscle-invasive bladder cancer (NMIBC) but is frequently associated with significant local and systemic adverse effects. This study aimed to investigate the effects of Uro-Vaxom (UVX) on BCG-related infectious adverse events and oncologic outcomes in patients with NMIBC.

Materials and methods

This retrospective cohort study included 251 NMIBC patients who underwent BCG induction therapy following transurethral resection of bladder tumors at a single institution. Patients were stratified into two groups: those not receiving UVX (non-UVX group, n=142) and those receiving UVX (UVX group, n=109). Clinical and oncologic parameters, including the frequency of antibiotic use, treatme

SUBMITTER: Cho S 

PROVIDER: S-EPMC12277912 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature